UBS Upgrades Quest Diagnostics (DGX) to Buy
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
UBS upgraded Quest Diagnostics (NYSE: DGX) from Neutral to Buy with a price target of $90.
Analyst A.J. Rice said, "At its investor day on November 11, Quest management laid out the growth outlook for the company's next 3-5 years. From 2017 to 2020, DGX expects to post annual revenue growth of 3-5%, with 1-2% coming from acquisitions. Earnings growth over the same period is expected to be in the mid-to-single digit percentage growth range. Finally, free cash flow is projected to grow in the high single digit growth range. These growth targets represent reiterations and in some cases increases in company targets. In addition, DGX management says it approached the outlook in a way that leaves the potential it can be at the high end of expectations."
Shares of Quest Diagnostics closed at $81.46 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Raises Price Target on Zumiez, Inc. (ZUMZ) to $23 Following 3Q
- FBR Capital Cuts Price Target on Express (EXPR) Following 3Q EPS Miss
- Jefferies Cuts Price Target on Kroger (KR) to $30 Following 3Q and Guidance
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, Upgrades
Related EntitiesUBS, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!